1	Trends in the 30-year span of Noninfectious Cardiovascular Implantable Electronic Device
2	Complications in Olmsted County
3	Gurukripa N. Kowlgi, MBBS ¹ ; Vaibhav Vaidya, MBBS ¹ ; Ming-Yan Dai ¹ ; Rahul Mishra ¹ ; David
4	O. Hodge ³ ; Abhishek J. Deshmukh, MBBS ¹ ; Siva K. Mulpuru, MD, MPH; Paul A. Friedman,
5	MD; Yong- Mei Cha, MD ¹
6	1. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA
7	2. Department of Quantitative Health Sciences, Jacksonville, FL 32224, USA
8	
9	Word count: 4902 words
10	
11	Corresponding author:
12	Yong-Mei Cha, MD, FHRS
13	Professor of Medicine
14	Mayo Clinic, 200 First St SW
15	Rochester, MN 55905, USA
16	E-mail: <u>ycha@mayo.edu</u> ;
17	Phone: 5072843585; Fax: 5072552550
18	
19	

20 Abstract:

21	Background: Cardiovascular implantable electronic devices (CIEDs) such as permanent
22	pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization therapy
23	devices alleviate morbidity and mortality in various diseases. There is a paucity of real-world
24	data on CIED complications and trends.
25	Objectives: Describe trends in noninfectious CIED complications over the past three decades in
26	Olmsted County.

Methods: The Rochester Epidemiology Project is a medical records linkage system comprising
records of over 500,000 residents of Olmsted County from 1966-current. CIED implants between
1988-2018 were determined. Trends in noninfectious complications within 30 days of implant
were analyzed.

Results: 175 out of 2536 (6.9%) patients who received CIED experienced device complications.
3.8% of the implants had major complications requiring intervention. Lead dislodgement was the
most common (2.9%), followed by hematoma (2.1%). Complications went up from 1988 to
2005, then showed a downtrend until 2018, driven by a decline in hematomas in the last decade
(p<0.01). Those with complications were more likely to have prosthetic valves. Obesity appeared</p>
to have a protective effect in a multivariate regression model. The mean Charlson comorbidity
score has trended up over the 30 years.

38 Conclusions: Our study describes a real-world trend of CIED complications over three decades.
39 Lead dislodgements and hematomas were the most common complications. Complications have
40 declined over the last decade due to safer practices and a better understanding of anticoagulant
41 management.

- 42 Key Words: Cardiovascular implantable electronic devices, pacemaker, implantable
- 43 cardioverter-defibrillator, cardiac resynchronization therapy, complications.
- 44

45 Abbreviations:

- 46 CIED: Cardiac Implantable Electronic Devices
- 47 ICD: Implantable Cardioverter-Defibrillator
- 48 PPM: Permanent Pacemaker
- 49 CRT: Cardiac Resynchronization Therapy
- 50 CRT-P: Cardiac Resynchronization Therapy Pacemaker
- 51 CRT-D: Cardiac Resynchronization Therapy Defibrillator
- 52 FDA: Food and Drug Administration
- 53 REP: Rochester Epidemiology Project
- 54 ICD-9/10: International Classification of Diseases 9th /10th Revision
- 55 CPT: Current Procedural Terminology
- 56 NIS: National Inpatient Sample
- 57 NCDR: National Cardiovascular Data Registry

58

59 **Introduction:**

Cardiac implantable electronic devices (CIEDs) such as the permanent pacemaker (PPM),
 implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT)
 systems are ubiquitously employed for managing a variety of cardiac arrhythmia and
 comorbidities. In recent years, we have witnessed an expansion in the indications for CIED
 implantation¹⁻⁴. CIEDs have augmented patient quality of life, reduced hospitalization length,
 and reduced mortality⁵⁻⁷.

Notwithstanding substantial technological improvements, complications involving CIED
implants remain a significant issue^{8–10}. Acute complications of CIED implants include lead
dislodgement, perforation, pneumothorax, pocket hematoma, infection, and upper extremity deep
vein thrombosis (DVT)^{8–11}. With an increase in life expectancy and expanding CIED implant
indications, implant-related adverse events are anticipated^{12–14}. Device complications are critical
to detect and manage to improve patient safety, prevent reoperations, reduce the length of
hospital stay, and mitigate downstream healthcare costs^{15,16}.

The majority of what we know about CIED complications is curated from secondary analysis of randomized trials^{10,17}, registry-based studies^{18,19}, or hospital-based databases^{15,20}. Administrative-claims-based databases have been shown to have low specificity in determining true CIED complications ²¹. There exists a paucity of real-life population-based data on the incidence, trends, and predictors of CIED complications. There exists a paucity of real-life population-based data on the incidence, trends, and predictors of CIED complications. Our group has previously published data on the trends of CIED infections ¹⁴. In the present study, we

80 present retrospective population-based data on the noninfectious mechanical CIED

81 complications between 1988 and 2018.

82 Methods:

83 Data source

Our study was approved by the Mayo Clinic Institutional Review Board and received proper 84 85 ethical oversight. Data were obtained from the Rochester Epidemiology Project (REP). The REP is a medical records linkage system containing medical records of all residents of Olmsted 86 County, MN, from January 1, 1966, to the present, consisting of follow-up data on more than 87 88 500,000 unique individuals. Patient demographics, diagnostic codes such as the international classification of diseases 9th and 10th revision (ICD-9/10-CM) codes, and surgical procedure 89 codes are recorded for all individuals. Paper and electronic medical records of these individuals 90 91 are available for the generation of additional data. The REP permits the collection of populationbased data and has been used to define the incidence of various medical conditions. It consists of 92 93 two major hospital systems in Olmsted County (Mayo Clinic and Olmsted Medical Center) and smaller practices. 94

95 *Study population*

96 The REP database was used to determine all patients who received CIED implantation between 97 1988 and 2018. During the study period, Mayo Clinic and Olmsted Medical Center were the only 98 two institutions in Olmsted County performing CIED implantation and follow-up. There were 99 four device implanters in the early 1990s and ten in 2018. Patients receiving CIEDs were 90 determined based on ICD-9 CM and ICD-10 PCS codes. Data on subsequent device upgrades 91 from PPM to ICD or CRT or ICD to CRT were collected using ICD-9 and 10 codes and

102 manually verified. For this study, we only included procedures that involved intracardiac lead implantation. Thus, subcutaneous ICDs, generator change, and device extraction without lead 103 implantation/revision were excluded. Data regarding baseline demographics and comorbidities 104 were obtained from the REP and abstracted from the medical records. The patients' charts with 105 device complications were manually reviewed to confirm the complications. The Charlson 106 comorbidity index is a score derived from multiple risk factors that predict 1-year survival and 107 can be used as a surrogate for comorbidity. CCI was calculated for all patients at the time of the 108 CIED implant. The unique complications were defined by a composite of ICD-9 and ICD-10 109 110 diagnosis codes, summarized in the **Supplemental Tables 1A-E**. For lead dislodgement, we used codes for a lead revision within 30 days and confirmed lead dislodgement through manual 111 chart review. The clinical definitions for post-implant complications for this study are as follows. 112 Notably, repeat surgical intervention was not a criterion to code the complications, and even 113 those that were conservatively managed were included. 114 Perforation: Any new pericardial effusion, with or without hemodynamic compromise. 115 Hematomas: Any pocket bleeding that led to interruption of oral anticoagulant therapy, 116 prolonged hospitalization > 24 hours. 117 Pneumothorax: Any pneumothorax detected on post-procedure chest radiography 118 Lead dislodgement: Included macro-dislodgement as evident on a chest radiograph, and micro-119 dislodgement that were detected based on acute rise in capture thresholds. 120 Statistical analysis 121 Normally distributed continuous variables and expressed as mean \pm standard deviation. The 122

123 overall frequency of CIED complications was determined using the number of complications

124	divided by the population at risk (device implants) in Olmsted County in the same period. Trends
125	in complications over time, across age groups, and between genders are estimated using Poisson
126	regression models. Comparisons between implant groups for categorical factors were completed
127	using Chi-square tests. Continuous factors were compared between groups using the analysis of
128	Variance. Overall survival was estimated using the Kaplan-Meier method. These curves were
129	compared between groups using log-rank tests. P-values less than 0.05 were considered
130	significant. All analysis was completed using SAS version 9.4.

131 **Results:**

132 Population characteristics:

Between 1988 and 2018, there were 2536 CIED initial implants in Olmsted County, including 133 1927 PPMs (single and dual-chamber), 440 ICDs, and 169 CRT (pacemaker and defibrillator) 134 135 devices. The mean age at device implantation was 73.9 ± 14.3 years. Women comprised 42.1%of all CIED recipients in the study. 197 complications were seen in 175 (6.9%) patients. There 136 was a significant difference in some baseline characteristics among patients with and without 137 138 CIED complications (Table 1). Patients with CIED complications were more likely to have prosthetic valves and less likely to be obese or diabetic. Of the 197 complications, there were 75 139 (2.9%) lead dislodgements, 53 (2.1%) pocket hematomas, 42 (1.6%) pneumothoraces, and 27 140 (1.1%) cardiac perforations (Table 2). Patients with cardiac perforation were more likely to be 141 female and less likely to have cardiomyopathy (Table 3). There was a higher frequency of 142 cardiomyopathy, prosthetic valves, and stroke in those patients who suffered pocket hematomas. 143 Patients with pneumothoraces were older, more likely to be females, and less likely to have 144 obesity or cardiomyopathy. There was no demographic predisposition to lead dislodgement. 145

146 *Summary of complications*

147	Of the patients with complications, 97 (3.8% of all implants) were classified as major
148	complications requiring a procedural intervention as described. The number of complications per
149	patient was one $(133/175)$, two $(18/175)$, or three $(2/175)$. Over three-quarters of the patients
150	with complications (135/175) had PPM implants. Sixteen percent of the patients with
151	complications (28/175) underwent ICD implantation, and the remaining 6.9% (12/175) occurred
152	in the CRT group. The complication rates in pacemakers, ICD, and CRT were 7%, 6.4%, and
153	7.1% (p=NS).
154	Of the 27 (1.1%) patients who had perforations, about half required pericardiocentesis

(13/27). Only 5.7% (3/53) of the patients who developed hematomas required pocket re-entry to 155 156 resolve the bleeding. The majority (88.7%) of the patients who developed hematomas were on either anticoagulation or antiplatelet medications or both, with 16.9% (9/53) receiving 157 periprocedural heparin (all before 2013). More than two-thirds [69.1%, (29/42)] of patients with 158 159 pneumothoraces were managed conservatively, and the rest required chest tube placement temporarily before resolution. Of the 75 patients with lead dislodgement, 35 (46.7%) had atrial 160 lead dislodgement, 35 (46.7%) had their right ventricular lead dislodged, and 5 (5.3%) had their 161 coronary sinus lead dislodged. Ninety-two percent of patients (69/75) had to have their dislodged 162 lead revised. 163

164 *Temporal trends in CIED complications:*

165 Temporal trends were compared between five intervals: 1988-93, 94-99, 2000-2005, 2006-11,

and 2012-18. There was a significant change in the proportion of complications over time

167 (Figure 1). The total complications increased between 1988-93 to 2000-05; from 2.1% to 10.1%;

168	and subsequently decreased to 7.7% in 2012-2018, p=0.001. Similar trends were noted for
169	hematomas, p<0.01. There were variations in the frequencies of patients with perforations,
170	pneumothoraces, and lead dislodgement; however, these were not statistically significant.
171	In relation to total implants, the percentage of pacemakers implanted has steadily
172	declined over the years. The age and sex-adjusted incidence of PPM implantation increased
173	between 1988-93 and 2000-05; then decreased in 2012-2018. The age and sex-adjusted incidence
174	of ICD implantation increased between 1988-93 and 2000-05, then decreased in 2012-2018. In
175	contrast, the age and sex-adjusted incidence of CRT implantation continued to increase
176	significantly from 2000-05 to 2012-18(Figure 2A) ²² . The complications trends showed an initial
177	increase in these groups followed by a decline in more recent years, statistically significant
178	within each group, $p < 0.05$ (Figure 2B).
179	Age and sex trends in CIED complications
180	When stratified by age, the percentage of implants for all periods was the lowest in patients < 50
181	years, higher in 50-70 years, and highest in patients > 70 years of age, p<0.01 (Figure 3A). The
182	trend of complications in patients >50 years increased from 1988 to 2005 and then trended down
183	(p< 0.05). In patients under 50 years of age, the frequency of the complications rose from 1988-
184	93 to 2000-2005, decreased in 2006-2011, and then increased again in 2012-18, although
185	statistically not significant (Figure 3B).
186	Of the 175 patients with complications, 93 were males (53.1%), and 82 (46.9%) were

period. (Figure 4A). Within females, the complications increased from 1988-93 to 2000-05 and 188

- reached a plateau in recent years. In males, complications went up from 1988-93 to 2000-05 and
 then decreased until 2012-2018 (p<0.01) (Figure 4B).
- 191 *Trends in comorbidities and predictors of complications*
- 192 Using the Charlson comorbidity index (CCI), patients' comorbidities receiving CIED have
- increased over time (Table 4). However, there was no statistical difference between the CCI of
- 194 patients with complications and those who did not within each time frame. When analyzed
- separately for each complication subtype, the only significant difference was noted in patients
- 196 with hematoma from 2000-2011, who had higher CCI than those without. (Supplemental
- **Tables 2-5**). When controlled for other factors, utilizing a multivariate regression model, the
- presence of prosthetic valves, OR 1.62 (1.11, 2.37), p = 0.01, was independently associated with
- 199 a higher risk of noninfectious complications. Obesity was independently associated with a lower
- risk of noninfectious complications, OR 0.68 (0.40, 0.95), p = 0.02.
- 201 Overall survival after CIED implantation

The median follow-up was six years (interquartile range 3.0-10.9 years). Survival after CIED 202 203 complication was 63.2% at five years (95% CI 55.9-70.4) and 35.4% (95% CI 27.4-43.4) at ten 204 years, compared to 61.7% (95% CI 59.8-63.6), and 42.6% (95% CI 40.4-.44.8) respectively in patients without complications (p=0.07) (Figure 5A). After PPM, ICD, and CRT implantation 205 complications, the survival was 35.8% (95% CI 26.7-44.9%), 38.2% (95% CI 18.9-57.5), and 206 207 15.6% (95% CI 0.0-43.2%), at ten years, respectively. In the PPM, ICD, and CRT implants without complications, the ten-year survival was 40.6% (95% CI 38.1-43.1, p =0.25) 53.0% 208 (95% CI 46.5-58.55%, p=0.10), and 43.5% (95% CI 33.0-54.0%, p=0.67) (Figure 5BCD). 209

Females and males with a complication did not significantly differ in survival compared to those
without (p=0.21 and 0.20, respectively). (Figure 6)

212 **Discussion:**

Using a large population-based record-linkage study, we describe trends in the noninfectious 213 complications of CIED implantation. Our principal findings are (1) Lead dislodgement is the 214 most common noninfectious complication after CIED implant, followed by hematoma, 215 pneumothorax, and cardiac perforation. (2) The overall complications showed an up-trend from 216 1988 to 2005 and have reduced in frequency from 2005 to 2018. (3) The prevalence of 217 complications is higher in patients over 50 years of age than younger patients. (4) The 218 comorbidities of patients receiving CIED implants have steadily increased over time. (5) The 219 220 presence of prosthetic heart valves was an independent predictor of noninfectious complications (6) Obesity tends to confer an independent risk-reduction concerning noninfectious CIED 221

- complications. (7) Long-term survival of patients with acute CIED complications was not
- 223 different from those without complications but trended towards statistical significance.

224 Incidence of noninfectious complications:

The overall incidence of acute (30-day) noninfectious complications after CIED implants from 1988 to 2018 was estimated to be 6.9%, and that of major complications requiring intervention was 3.8%. Prior studies have shown wide variability in the percentage of complications (7-18%) due to heterogeneity in study populations, the definition of complications, data sources, and follow-up duration. ^{10,11,19,23–25} Our findings seem to correlate with those reported by prior population-based studies ^{23,25}. However, there exists a discrepancy between the results of

231	population-based studies,	those obtained	from administrativ	ve and claims	databases ^{11,26,27} ,

232 National ICD Registry ^{18,28}, and those from large-scale clinical trials. ^{10,17}

While clinical trials are gold-standard for assessing the effects of an intervention, the 233 inclusion criteria are often quite strict, rendering a challenge in the generalization of observed 234 events to the population.²⁹ Largescale databases, while reflecting the real-world scenario, are 235 fraught with issues regarding the accuracy of data and lack of detailed follow-up. Therefore, a 236 population-based medical record linkage system such as the REP serves as an intermediary and 237 is crucial for mitigating the limitations of alternative data sources. The definitions used in our 238 study for the complications were more inclusive than prior studies as our goal was to identify 239 240 major and minor complications, and their predictors.

241 *Trends in device complications:*

Our group has previously described that the incidence of CIED implants in Olmsted County 242 increased gradually from 1988 to 2005. However, from 2005 to 2018, a decline in CIED 243 implants has been driven by a reduction in PPM and ICD implants²². The overall trend of CIED 244 complications has been similar, increasing from 1988-93 to 2000-05, followed by a downtrend 245 until 2012-18. The individual trends of lead dislodgement, hematoma, pneumothorax, and 246 perforation followed the overall trends with slight variations when they peaked in the mid-2000s. 247 While no prior studies have encompassed three decades of data, the trends seem to follow the 248 most extensive reports from each period. ^{10,17,18,23,25,30} These data appear closely related to the 249 previously described trends with *infectious* CIED complications ¹⁴. The initial rise in 250 complications seen from 1988 to 2005 reflects the increase in PPM in an aging population and 251 expanding ICD indications for sudden death prevention, and the increase in the comorbidity 252

burden^{14,22}. Improved implantation techniques, use of micropuncture needles, and imaging-

guided access, with better periprocedural anticoagulation strategies, may have contributed to the subsequent decline in complications $^{31-33}$.

256 *Predictors of complications*

Notably, the mean age of CIED implants at our institution was higher than in most prior
population studies and trials¹⁴. Furthermore, our patients with 77% coronary artery disease, 75%
valvular disease, 74% heart failure, 71% atrial fibrillation, and 62% diabetes mellitus, among
others, represent a much sicker baseline population than prior studies^{18–20,23,34}.

The presence of prosthetic heart valves was an independent predictor of noninfectious complications after adjusting for other implicated factors in device complications. These could be attributed to longer procedure times due to intricate and complex anatomy and the higher propensity to be on anticoagulation. The incidence of hematoma was reduced after 2011, likely reflecting the advantage of uninterrupted oral anticoagulation, a lower risk of pocket bleeding compared to heparin bridging.³⁵

267 Interestingly, obesity was shown to have an independent protective effect against 268 noninfectious complications. The reverse epidemiology or obesity paradox is a well-established entity in chronic disease conditions and has recently been extrapolated to thoracic surgeries and 269 CIED implants.^{36–39} Several mechanisms have been postulated to explain the obesity paradox, 270 271 but the most relevant for CIED outcomes appear to be less cardiac cachexia, improved nutritional status, and better metabolic reserve with lower sarcopenia.^{36,39} Obese patients tend to 272 273 have a higher prevalence of comorbid conditions such as hypertension, diabetes, and sleep apnea that require closer periprocedural monitoring and may contribute to improved outcomes. This 274

275	phenomenon is further evidenced by the extension of the obesity paradox to the critical care
276	literature. ⁴⁰ It is important to note that the protective effects of obesity are likely lost at extreme
277	body mass indices (>40 kg/m ^{2}), due to an increase in procedural time and complexity, with
278	increased fluoroscopy duration. ²³

279 Survival after device implantation and sex considerations:

Data regarding long-term survival after CIED complications are sparse. We describe no
significant difference in the 5-year and 10-year survival in patients without acute noninfectious
CIED complications compared to patients with complications, although trending towards
statistical significance.

Prior studies have shown that females are more likely to have short-term CIED complications.^{23,41} While we saw a higher proportion of women in the patients that suffered a pneumothorax or perforation in our study, female sex was not an independent predictor of complications when adjusted for age and comorbid conditions. Additionally, females with acute CIED complications had no difference in long-term survival compared to males.

289 Limitations:

Despite the benefits of having access to extensive population-based linkage data, our study has several limitations. Akin to any observational study, we cannot rule out the confounding effect due to unmeasured variables. Our sample consists predominantly of Caucasians, especially among the elderly. Prior studies have suggested that the data obtained from the REP could be generalized to a large percentage of the United States population. This may be inconsistent, especially when applied to populations with a higher proportion of ethnic minorities. We were also limited in using ICD codes for CIED implantation, which may have underestimated the

actual counts of procedures and comorbid conditions. Yet, the number of CIED implantations is
consistent with previous REP studies with manual verification of all implantations and
complications.

Although our data is population-based, most of the CIED-related care during the study period was provided by a single large tertiary hospital, which may have different practice patterns than community-based practices. While we understand that initial implants have a different risk profile than revisions, and generator replacements, we did not have a significant number of complications in lead revisions or device upgrades to make meaningful comparisons to de novo implants.

306 **Conclusions:**

307 CIED implant complications cause morbidity and may require re-intervention, but not associated 308 with long term mortality. The frequency of acute noninfectious complications has been gradually 309 decreasing in recent years, likely owing to safer practices. Prosthetic heart valves appear to be an 310 independent risk factor for complications, while obesity seems protective, supplementing the 311 growing obesity paradox literature. Close monitoring of the trends and consistent vigilance 312 would be needed to maintain the downtrend of CIED complications.

313 Funding Support and Author Disclosures:

314 This study was made possible using the resources of the Rochester Epidemiology Project,

315 which is supported by the National Institute on Aging of the National Institutes of Health under

316 Award Number R01AG034676. The content is solely the responsibility of the authors and does

317 not necessarily represent the official views of the National Institutes of Health.

318	The	study is supported by the Mayo Clinic, Department of Cardiovascular Medicine, and
319	Med	tronic Inc. research funding. Paul A. Friedman is the global principal investigator on the
320	Med	tronic extravascular ICD study, and has served as an advisor, with all funds going to Mayo
321	Clini	c. Siva K. Mulpuru is on the Biotronik SICD advisory board, NIH CICS study section,
322	recei	ved funding from Mayo Clinic Prospective study grant, and a Biosense Webster educational
323	conf	erence participant. Yong-Mei Cha received research funding from Medtronic Inc. The other
324	autho	ors have no relevant disclosures.
325		
326	Refe	rences:
327	1.	Uslan DZ, Tleyjeh IM, Baddour LM, Friedman PA, Jenkins SM, St Sauver JL, et al.
328		Temporal trends in permanent pacemaker implantation: A population-based study. Am
329		Heart J 2008;155:896–903. doi:10.1016/j.ahj.2007.12.022.
330	2.	Merriam JA, Rajendra AB, Gold MR. Newer indications for ICD and CRT. Cardiol Clin
331		2014;32:181–190. doi:10.1016/j.ccl.2013.12.004.
332	3.	Das M. Indications for ICD and cardiac resynchronization therapy for prevention of
333		sudden cardiac death. Expert Rev Cardiovasc Ther 2009;7:181–195.
334		doi:10.1586/14779072.7.2.181.
335	4.	Kowlgi GN, Giudicessi JR, Barake W, Bos JM, Ackerman MJ. Efficacy of intentional
336		permanent atrial pacing in the long-term management of congenital long QT syndrome. J
337		Cardiovasc Electrophysiol 2021;32:782–789. doi:10.1111/JCE.14920.
338	5.	Atreya AR, Cook JR, Lindenauer PK. Complications arising from cardiac implantable

339		electrophysiological devices: Review of epidemiology, pathogenesis and prevention for
340		the clinician. Postgrad Med 2016;128:223-230. doi:10.1080/00325481.2016.1151327.
341	6.	Zhan C, Baine WB, Sedrakyan A, Steiner C. Cardiac device implantation in the United
342		States from 1997 through 2004: A population-based analysis. J Gen Intern Med
343		2008;23:13–19. doi:10.1007/s11606-007-0392-0.
344	7.	Cleland JGF, Daubert J-CC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al.
345		The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl
346		J Med 2005;352:1539–1549. doi:10.1056/NEJMoa050496.
347	8.	Hauser RG, Hayes DL, Kallinen LM, Cannom DS, Epstein AE, Almquist AK, et al.
348		Clinical experience with pacemaker pulse generators and transvenous leads: An 8-year
349		prospective multicenter study. Hear Rhythm 2007;4:154–160.
350		doi:10.1016/j.hrthm.2006.10.009.
351	9.	Udo EO, Zuithoff NPA, Van Hemel NM, De Cock CC, Hendriks T, Doevendans PA, et
352		al. Incidence and predictors of short- and long-term complications in pacemaker therapy:
353		The FOLLOWPACE study. Hear Rhythm 2012;9:728–735.
354		doi:10.1016/j.hrthm.2011.12.014.
355	10.	Ellenbogen KA, Hellkamp AS, Wilkoff BL, Camunãs JL, Love JC, Hadjis TA, et al.
356		Complications arising after implantation of DDD pacemakers: The MOST experience.
357		Am J Cardiol 2003;92:740–741. doi:10.1016/S0002-9149(03)00844-0.
358	11.	Koneru JN, Jones PW, Hammill EF, Wold N, Ellenbogen KA. Risk factors and temporal
359		trends of complications associated with transvenous implantable cardiac defibrillator

360	leads. J Am Heart Assoc 2018;7. doi:10.1161/JAHA.117.007691.
-----	--

361	12.	Landolina M, Gasparini M, Lunati M, Iacopino S, Boriani G, Bonanno C, et al. Long-term
362		complications related to biventricular defibrillator implantation: Rate of surgical revisions
363		and impact on survival: Insights from the italian clinicalservice database. Circulation
364		2011;123:2526–2535. doi:10.1161/CIRCULATIONAHA.110.015024.
365	13.	Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al.
366		2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With
367		Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the
368		American College of Cardiology/American Heart Association Task Force on Clinical
369		Practice Guidelines, and the Heart Rhythm Society. J Am Coll Cardiol 2019;74:932–987.
370		doi:10.1016/j.jacc.2018.10.043.
371	14.	Dai M, Cai C, Vaibhav V, Sohail MR, Hayes DL, Hodge DO, et al. Trends of
372		Cardiovascular Implantable Electronic Device Infection in 3 Decades: A Population-
373		Based Study. JACC Clin Electrophysiol 2019;5:1071–1080.
374		doi:10.1016/j.jacep.2019.06.016.
375	15.	Tobin K, Stewart J, Westveer D, Frumin H. Acute complications of permanent pacemaker
376		implantation: Their financial implication and relation to volume and operator experience.
377		Am J Cardiol 2000;85:774–776. doi:10.1016/S0002-9149(99)00861-9.
378	16.	Al-Khatib SM, Anstrom KJ, Eisenstein EL, Peterson ED, Jollis JG, Mark DB, et al.
379		Clinical and Economic Implications of the Multicenter Automatic Defibrillator
380		Implantation Trial-II. Ann Intern Med 2005;142:593. doi:10.7326/0003-4819-142-8-
381		200504190-00007.

382	17.	Van Eck JWM, Van Hemel NM, Zuithof P, Van Asseldonk JPM, Voskuil TLHM,
383		Grobbee DE, et al. Incidence and predictors of in-hospital events after first implantation of
384		pacemakers. Europace 2007;9:884-889. doi:10.1093/europace/eum113.
385	18.	Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. Dual-chamber
386		implantable cardioverter-defibrillator selection is associated with increased complication
387		rates and mortality among patients enrolled in the NCDR implantable cardioverter-
388		defibrillator registry. J Am Coll Cardiol 2011;58:1007–1013.
389		doi:10.1016/j.jacc.2011.04.039.
390	19.	Lee DS, Krahn AD, Healey JS, Birnie D, Crystal E, Dorian P, et al. Evaluation of Early
391		Complications Related to De Novo Cardioverter Defibrillator Implantation. Insights From
392		the Ontario ICD Database. J Am Coll Cardiol 2010;55:774–782.
393		doi:10.1016/j.jacc.2009.11.029.
394	20.	Duray GZ, Schmitt J, Cicek-Hartvig S, Hohnloser SH, Israel CW. Complications leading
395		to surgical revision in implantable cardioverter defibrillator patients: Comparison of
396		patients with single-chamber, dual-chamber, and biventricular devices. Europace
397		2009;11:297-302. doi:10.1093/europace/eun322.
398	21.	Boggan JC, Baker AW, Lewis SS, Dicks K V., Durkin MJ, Moehring RW, et al. An
399		Automated Surveillance Strategy to Ide.jpegy Infectious Complications After Cardiac
400		Implantable Electronic Device Procedures. Open Forum Infect Dis 2015;2:1-8.
401		doi:10.1093/ofid/ofv128.
402	22.	Vaidya VR, Asirvatham R, Kowlgi GN, Dai M-Y, Cochuyt JJ, Hodge DO, et al. Trends in
403		Cardiovascular Implantable Electronic Device Insertion Between 1988 and 2018 in

404		Olmsted County. JACC Clin Electrophysiol 2021. doi:10.1016/j.jacep.2021.06.006.
405	23.	Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after
406		cardiac implantable electronic device implantations: An analysis of a complete,
407		nationwide cohort in Denmark. Eur Heart J 2014;35:1186–1194.
408		doi:10.1093/eurheartj/eht511.
409	24.	Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al.
410		Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study.
411		Circulation 2014;129:837-847. doi:10.1161/CIRCULATIONAHA.113.005119.
412	25.	Ranasinghe I, Labrosciano C, Horton D, Ganesan A, Curtis JP, Krumholz HM, et al.
413		Institutional variation in quality of cardiovascular implantable electronic device
414		implantation. Ann Intern Med 2019;171:309-317. doi:10.7326/M18-
415		2810/SUPPL_FILE/M18-2810_SUPPLEMENT.PDF.
416	26.	Lin YS, Hung SP, Chen PR, Yang CH, Wo HT, Chang PC, et al. Risk Factors Influencing
417		Complications of Cardiac Implantable Electronic Device Implantation: Infection,
418		Pneumothorax and Heart Perforation: A Nationwide Population-Based Cohort Study.
419		Medicine (Baltimore) 2014;93. doi:10.1097/MD.000000000000213.
420	27.	Cantillon DJ, Exner D V., Badie N, Davis K, Gu NY, Nabutovsky Y, et al. Complications
421		and Health Care Costs Associated With Transvenous Cardiac Pacemakers in a Nationwide
422		Assessment. JACC Clin Electrophysiol 2017;3:1296–1305.
423		doi:10.1016/J.JACEP.2017.05.007.
424	28.	Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, et al. Survival of

425		Patients Receiving a Primary Prevention Implantable Cardioverter-Defibrillator in Clinical
426		Practice vs Clinical Trials. JAMA 2013;309:55-62. doi:10.1001/JAMA.2012.157182.
427	29.	Milan D, Singh JP. Device implantation and complications: time to recalibrate our
428		expectations? Eur Heart J 2014;35:1167-1168. doi:10.1093/EURHEARTJ/EHT568.
429	30.	Parsonnet V, Bernstein AD, Lindsay B. Pacemaker-implantation complication rates: An
430		analysis of some contributing factors. J Am Coll Cardiol 1989;13:917-921.
431		doi:10.1016/0735-1097(89)90236-2.
432	31.	Nicholson D, Flisak M, Abudayyeh I, Dihu J, Patel P. Complications Associated with
433		Venipuncture During Cardiac Device Implantation are Significantly Reduced with
434		Utilization of Micropuncture Needle. Circ Arrhythmia Electrophysiol 2011;124.
435		doi:10.1161/CIRCEP.115.002921.
436	32.	Ramza BCM, Rosenthal L, Hui R, Nsah E, Savader S, Lawrence JH, et al. Safety and
437		Effectiveness of Placement of Pacemaker and Defibrillator Leads in the Axillary Vein
438		Guided by Contrast Venography. Am J Cardiol 1997;80:892-896. doi:10.1016/S0002-
439		9149(97)00542-0.
440	33.	Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or
441		Defibrillator Surgery without Interruption of Anticoagulation. N Engl J Med
442		2013;368:2084–2093.
443		doi:10.1056/NEJMOA1302946/SUPPL_FILE/NEJMOA1302946_DISCLOSURES.PDF.
444	34.	da Silva KR, Albertini CM de M, Crevelari ES, de Carvalho EIJ, Fiorelli AI, Filho MM, et
445		al. Complications after Surgical Procedures in Patients with CardiacImplantable

446	Electronic Devices: Results of a ProspectiveRegistry. Arq Bras Cardiol 2016;107:24	45.
447	doi:10.5935/ABC.20160129.	

- 448 35. Li HK, Chen FC, Rea RF, Asirvatham SJ, Powell BD, Friedman PA, et al. No increased
- bleeding events with continuation of oral anticoagulation therapy for patients undergoing
- 450 cardiac device procedure. Pacing Clin Electrophysiol 2011;34:868–874.
- 451 doi:10.1111/J.1540-8159.2011.03049.X.
- 452 36. Jahangir A, Mirza M, Shahreyar M, Mengesha T, Shearer R, Sultan S, et al. Presence of
- 453 obesity is associated with lower mortality in elderly patients with implantable cardioverter

454 defibrillator. Int J Obes 2018 422 2017;42:169–174. doi:10.1038/ijo.2017.211.

- 455 37. Il'Giovine ZJ, Patel D, Kumar A, Trulock K, Ann Moennich L, Donnellan E, et al.
- 456 Obesity predicts survival after cardiac resynchronization therapy independent of effect on

457 left ventricular ejection fraction. Circ Hear Fail 2020.

- 458 doi:10.1161/CIRCHEARTFAILURE.120.007424.
- 459 38. Tulinský L, Mitták M, Tomášková H, Ostruszka P, Penka I, Ihnát P. Obesity paradox in

460 patients undergoing lung lobectomy - Myth or reality? BMC Surg 2018;18:1–6.

461 doi:10.1186/S12893-018-0395-2/FIGURES/1.

- 462 39. Kowlgi GN, Siontis KC. Safety of catheter ablation in obese patients: Less complicated
- than you think. J Cardiovasc Electrophysiol 2022;33:664–666. doi:10.1111/JCE.15394.
- 464 40. Hutagalung R, Marques J, Kobylka K, Zeidan M, Kabisch B, Brunkhorst F, et al. The
- des obesity paradox in surgical intensive care unit patients. Intensive Care Med
- 466 2011;37:1793–1799. doi:10.1007/S00134-011-2321-2.

- 467 41. Peterson PN, Daugherty SL, Wang Y, Vidaillet HJ, Heidenreich PA, Curtis JP, et al.
- 468 Gender differences in procedure-related adverse events in patients receiving implantable
- 469 cardioverter-defibrillator therapy. Circulation 2009;119:1078–1084.
- 470 doi:10.1161/CIRCULATIONAHA.108.793463.

471

472 Figure legends:

- 473 Figure 1: Central illustration. Trends of overall CIED complications from 1988-2018. Trendlines are provided for perforations, hematomas,
- 474 pneumothoraces, lead dislodgements, and the mean Charlson Comorbidity Indices. CIED = cardiovascular implantable electronic device.
- 475 MADIT(Multicenter Automatic Defibrillator Implantation Trial); MOST (Multi-arm Optimization of Stroke Thrombolysis); DAVID (Dual Chamber
- 476 and VVI Implantable Defibrillator); DEFINITE (Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation); CRT (Cardiac
- 477 Resynchronization Therapy); ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation), ROCKET-AF
- 478 (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in
- 479 Atrial Fibrillation); DANISH (Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heart Failure on Mortality
- 480 Figure 2: The trends of CIED complications by device type. (A) Percentage of CIED implants in the year-group by device type (B) Frequency of

481 complications within device type. CIED = cardiovascular implantable electronic device; CRT = cardiac resynchronization therapy; ICD =

- 482 implantable cardioverter-defibrillator; PPM = permanent pacemaker.
- 483 Figure 3: The trends of CIED complications by age. (A) Percentage of CIED implants in the year-group by age-groups (B) Frequency of
- 484 complications within age groups. Abbreviations as in Figure 2.
- Figure 4: The trends of CIED complications by sex. (A) Percentage of CIED implants in the year-group by sex (B) Frequency of complications within sex groups. Abbreviations as in Figure 2.
- Figure 5: Survival Curves in (A) Total population, (B) PPM, (C) ICD, (D) CRT, based on the presence of complications or not. Abbreviations as in
 Figure 2.
- 489 Figure 6: Survival curves by sex and complications. F = Female; M = Male.
- 490
- 491
- 492
- 493
- . . .
- 494

495 Table 1: Baseline demographics for all patients.

All Complications

	Total (N=2536)	No Complications (N=2361)	Complications (N=175)	P value
Female sex	1068 (42.1%)	986 (41.8%)	82 (46.9%)	0.19
Mean Age (y)	73.9 ± 14.3	73.8 ± 14.3	74.8 ± 14.0	0.39
Atrial fibrillation	1790 (70.6%)	1665 (70.5%)	125 (71.4%)	0.80
CAD	1947 (76.8%)	1815 (76.9%)	132 (75.4%)	0.66
Cardiomyopathy	1166 (46.0%)	1086 (46.0%)	80 (45.7%)	0.94
Heart Failure	1858 (73.3%)	1728 (73.2%)	130 (74.3%)	0.75
СКD	1287 (50.7%)	1207(51.1%)	80(45.7%)	0.17
COPD	950 (37.5%)	882 (37.4%)	68 (38.9%)	0.69
Diabetes	1580 (62.3%)	1487 (63.0%)	93 (53.1%)	0.01

Heart transplant	40 (1.6%)	38 (1.6%)	2 (1.1%)	0.63
Hypertension	2206 (87.0%)	2048 (86.7%)	158 (90.3%)	0.18
Pulmonary hypertension	850 (33.5%)	783 (33.2%)	67 (38.3%)	0.17
Malignancy	1317 (51.9%)	1223 (51.8%)	94 (53.7%)	0.62
Obesity	1392 (54.9%)	1314 (55.7%)	78 (44.6%)	0.005
TIA/Stroke	843 (33.2%)	774 (32.8%)	69 (39.4%)	0.07
Valvular Disease	1906 (75.2%)	1766 (74.8%)	140 (80.0%)	0.12
Prosthetic Valve	436 (17.2%)	393 (16.7%)	43 (24.6%)	0.007
Implant type				0.89
CRT	169 (6.7%)	157 (6.7%)	12 (6.9%)	
ICD	440 (17.4%)	412 (17.5%)	28 (16.0%)	
Pacemaker	1927 (76.0%)	1791 (75.9%)	135 (77.1%)	

497 Table 2: Baseline demographics by type of complication.

	Perforatio	'n		Hematoma			Pneumoth	orax		Lead Dislo	dgement	
	No (N=2509)	Yes (N=27)	P value	No (N=2483)	Yes (N=53)		No (N=2494)	Yes (N=42)	P value	No (N=2459)		P value
Female sex	1050 (41.9%)	18 (66.7%)	0.009	1049 (42.3%)	19 (35.9%)	0.35	1044 (41.7%)	24 (57.1%)	0.05	1033 (42.0%)	35 (46.7%)	0.42
Mean Age (y)	73.9 ± 14.3	76.4 ± 12.2	0.34	73.9 ± 14.3	74.8± 15.0	0.62	73.8 ± 14.3	78.3± 11.5	0.04	73.9 ± 14.3	73.3± 13.9	0.72
Atrial fibrillation	1768 (70.5%)	22 (81.5%)	0.21	1752 (70.6%)	38 (71.7%)	0.86	1762 (70.7%)	28 (66.7%)	0.57	1734 (70.5%)	56 (74.7%)	0.43
CAD	1927 (76.8%)	20 (74.1%)	0.74	1905 (76.7%)	42 (79.3%)	0.67	1916 (76.8%)	31 (73.8%)	0.65	1893 (76.9%)	54 (72.0%)	0.32
Cardiomyopathy	1160 (46.3%)	6 (22.2%)	0.01	1132 (45.6%)	34 (64.2%)	0.007	1153 (46.2%)	13 (31.0%)	0.05	1129 (45.9%)	37 (49.3%)	0.55
Heart Failure	1841 (73.4%)	17 (63.0%)	0.22	1814 (73.1%)	44 (83.0%)	0.10	1825 (73.2%)	33 (78.6%)	0.43	1804 (73.3%)	54 (72.0%)	0.80
CKD	1276	11 (40.7%)	0.30	1259	28 (52.8%)	0.76	1268	19 (45.2%)	0.47	1254	33 (44.0%)	0.24

	(50.9%)			(50.7%)			(50.8%)			(51.0%)		
COPD	941 (37.5%)	9 (33.3%)	0.66	924 (37.2%)	26 (49.1%)	0.08	934 (37.5%)	16 (38.1%)	0.93	924 (37.6%)	26 (35.7%)	0.61
Diabetes	1564 (62.3%)	16 (59.3%)	0.74	1549 (62.4%)	31 (58.5%)	0.56	1560 (62.6%)	20 (47.6)	0.05	1540 (62.6%)	40 (53.3%)	0.10
Heart transplant	40 (1.6%)	0 (0.0%)	0.51	39 (1.6%)	1 (1.9%)	0.86	40 (1.6%)	0 (0.0%)	0.41	39 (1.6%)	1 (1.3%)	0.86
Hypertension	2179 (86.9%)	27 (100.0%)	0.04	2160 (87.0%)	46 (86.8%)	0.97	2167 (86.9%)	39 (92.9%)	0.25	2139 (86.9%)	67 (89.3%)	0.54
Pulmonary hypertension	840 (33.5%)	10 (37.0%)	0.70	828 (33.4%)	22 (41.5%)	0.21	833 (33.4%)	17 (40.5%)	0.34	825 (33.5%)	25 (33.3%)	0.97
Malignancy	1304 (52.0%)	13 (48.2%)	0.69	1285 (51.8%)	32 (60.4%)	0.21	1290 (51.7%)	27 (64.3%)	0.11	1281 (52.1%)	36 (48.0%)	0.49
Obesity	1378 (54.9%)	14 (51.8%)	0.75	1369 (55.1%)	23 (43.4%)	0.09	1377 (55.2%)	15 (35.7%)	0.01	1354 (55.0%)	38 (50.7%)	0.46
TIA/Stroke	833(33.2%)	10(37.0)	0.67	813(32.7%)	30(56.6%)	<0.001	830 (33.3%)	13 (31.0%)	0.75	818 (33.2%)	25 (33.3%)	0.99
Valvular Disease	1883 (75.1%)	23 (85.2%)	0.23	1861 (74.9%)	45 (84.9%)	0.1	1874 (75.1%)	32 (76.2%)	0.88	1847 (75.1%)	59 (78.7%)	0.48

	Prosthetic Valve	432 (17.2%)	4 (14.8%)	0.74	419 (16.9%)	17 (32.1%)	0.004	431 (17.3%)	5 (11.9%)	0.36	418 (17.0%)	18 (24.0%)	0.11
	Implant type			0.04			0.38			0.64			0.71
	CRT	168 (6.7%)	1 (3.7%)		164 (6.6%)	5 (9.4%)		166 (6.7%)	3 (7.1%)		165 (6.7%)	4 (5.3%)	
	ICD	440 (17.5%)	0 (0.0%)		428 (17.2%)	12 (22.6%)		435 (17.4%)	5 (11.9%)		429 (17.4%)	11 (14.7%)	
	Pacemaker	1901 (75.8%)	26 (96.3%)		1891 (76.2%)	36 (67.9%)		1892 (75.9%)	34 (81.0%)		1867 (75.9%)	60 (80.0%)	
498 499													
500													
501 502													
503													
504 505													
506	Table 3: Distribut	ion of comp	lications:										

Complications	Number (% of total implants)				
Lead dislodgement	75 (2.9%)				
	52 (2.4%)				
Hematoma	53 (2.1%)				
Pneumothorax	42 (1.6%)				
Perforation	27 (1.1%)				
Table 4: Charlson comorbidity index trends					

Year Group	Complications	Patients analyzed	Overall Mean Charlson Comorbidity Index [*]	Mean Charlson Comorbidity Index	P-value †
1988-1993	No	225	1.1 ± 1.3	1.1 ± 1.3	0.20
1900-1993	Yes	4	1.1 ± 1.5	0.3 ± 0.5	0.20
1994-1999	No	338	1.5 ± 1.5	1.5 ± 1.6	0.95
1554-1555	Yes	20	1.5 ± 1.5	1.6 ± 1.1	0.55
	No	525		2.0 ± 1.8	
2000-2005	Yes	53	2.0 ± 1.8	2.2 ± 1.8	0.51
	No	470		2.1 ± 1.8	0.45
2006-2011	Yes	42	2.1 ± 1.8	1.9 ± 2.1	0.45
	No	729		2.3 ± 1.9	
2012-2018	Yes	47	2.3 ± 1.9	2.3 ± 2.0	0.90

* The p-value for the Charlson Comorbidity Index trend across all periods was significant at < 0.01

[†] The p-values described in this column are comparing patients with and without complication for each time period

513


514 Table 5: Multivariate regression model for predictors of complications

Variable	Odds Ratio (95% Confidence Interval)	P-value
Male sex	0.82 (0.60, 1.14)	0.24
Age at event	1.01 (0.99, 1.02)	0.44
Atrial fibrillation	0.99 (0.68, 1.44)	0.94
Diabetes	0.73 (0.53, 1.02)	0.06
COPD	1.11 (0.80, 1.55)	0.52
CKD	0.80 (0.57, 1.12)	0.20
Valvular Disease	1.40 (0.91, 2.13)	0.12
Prosthetic Valves	1.62 (1.11, 2.37)	0.01
Obesity	0.68 (0.40, 0.95)	0.02
PPM implant	0.91 (0.48, 1.70)	0.76
ICD implant	0.93 (0.46, 1.90)	0.85

Abbreviations – COPD: Chronic Obstructive Pulmonary Disease; CKD: Chronic Kidney Disease; PPM: Permanent Pacemaker; ICD: Implantable Cardioverter-Defibrillator

515 Figure 1: Central illustration. Trends of overall CIED complications from 1988-2018. Trendlines are provided for perforations, hematomas,


516 pneumothoraces, lead dislodgements, and the mean Charlson Comorbidity Indices. CIED = cardiovascular implantable electronic device.




517


518 Figure 2: The trends of CIED complications by device type. (A) Percentage of CIED implants in the year-group by device type (B) Frequency of


- 519 complications within device type. CIED = cardiovascular implantable electronic device; CRT = cardiac resynchronization therapy; ICD =
- 520 implantable cardioverter-defibrillator; PPM = permanent pacemaker.



529 complications within age groups. Abbreviations as in Figure 2.







551

552 Figure 6: Survival curves by sex and complications. F = Female; M = Male.

